Pharsight

Lo Minastrin Fe patents expiration

LO MINASTRIN FE Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7704984 APIL Extended estrogen dosing contraceptive regimen
Feb, 2029

(5 years from now)

Lo Minastrin Fe is owned by Apil.

Lo Minastrin Fe contains Ethinyl Estradiol; Norethindrone Acetate.

Lo Minastrin Fe has a total of 1 drug patent out of which 0 drug patents have expired.

Lo Minastrin Fe was authorised for market use on 24 July, 2013.

Lo Minastrin Fe is available in tablet, chewable, tablet;oral dosage forms.

Lo Minastrin Fe can be used as prevention of pregnancy.

The generics of Lo Minastrin Fe are possible to be released after 02 February, 2029.

Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient

Market Authorisation Date: 24 July, 2013

Treatment: Prevention of pregnancy

Dosage: TABLET, CHEWABLE, TABLET;ORAL

More Information on Dosage

LO MINASTRIN FE family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic